PRODUCT

Introduction to Boryung
caring for people’s health

Main Products

A guide to Boryung’ main
products.

Products

A guide to all
Boryung’s products.

close

R&D

The Boryung Company,
envisioning a world with a
healthy mankind.

R&D Vision·Strategy

Boryung’ goal is to develop
into a global company.

Pipeline

The research team at Boryung
aims to lead the future of the
pharmaceutical industry.

close

GLOBAL
BUSINESS

An introduction of
Boryung’ global business.

Introduction

The best global company.

CMO

Introducing BRCMO business

Network

50 markets and 150 partners worldwide.

close

PR

An introduction of Boryung ’ value -
Envisioning a healthy mankind.

Advertising

An introduction of video
and printed advertisements of Boryung.

close

Directions

An introduction of Boryung
Pharmaceutical’ value - Envisioning
a healthy mankind.

Directions

An introduction of video
and printed advertisements of Boryung.

close

Financial Information

Summary of Consolidated Statements of Financial Position

(Unit : KRW 1,000,000 / As of December 31, 2024)

Summary of Consolidated Statements of Financial Position
Financial items 2024 2023 2022
Current assets 631,574 377,659 338,378
Non-current assets 532,513 537,852 554,008
Total assets 1,164,087 915,512 892,386
Current liabilities 239,339 201,083 227,483
Non-current liabilities 140,244 165,176 98,486
Total liabilities 379,584 366,259 375,969
Share capital 43,394 34,345 34,345
Other paid-in capital and Other components of equity 274,469 107,468 105,393
Retained earnings 466,641 406,936 376,179
Total equity 784,503 549,253 516,417

Summary of Consolidated Statements of Comprehensive Income

(Unit : KRW 1,000,000 / As of December 31, 2024)

Summary of Consolidated Statements of Comprehensive Income
Financial items 2024 2023 2022
Revenue 1,017,107 859,626 760,476
Cost of sales 653,750 506,196 453,289
Gross profit 363,357 353,430 307,187
Selling and administrative expenses 241,415 237,877 208,879
R&D expenses 51,469 47,286 41,705
Operating profit 70,472 68,267 56,603
Finance income 47,329 7,098 37,461
Finance costs 42,149 11,834 21,375
Other income 1,529 1,385 2,317
Other expenses 10,931 4,564 11,980
Share of loss of associates -3,291 -4,048 -4,154
Profit before income tax 62,959 56,306 58,872
Income tax expense -6,676 16,092 16,934
Profit for the year 69,636 40,213 41,938
Total comprehensive income for the year 67,297 37,293 48,796

Major financial ratio

(Unit : KRW 1,000,000 / As of December 31, 2024)

Major financial ratio
Financial items 2024 2023 2022
Revenue growth rate 18.32% 13.04% 21.23%
Profit growth rate 73.17% -4.11% -2.74%
ROA 5.98% 4.45% 4.87%
ROE 8.88% 7.55% 8.47%
Debt ratio 48.39% 66.68% 72.80%
Reserve ratio 1075.36% 1184.85% 1095.30%
Interest coverage ratio (times) 7.83 7.15 9.24

Analysis on profitability

(Unit : KRW 1,000,000 / As of December 31, 2024)

Analysis on profitability
Financial items 2024 2023 2022
Gross profit margin 35.72% 41.11% 40.39%
R&D investment ratio 5.06% 6.04% 6.09%
Selling and administrative expenses ratio 23.74% 27.67% 27.47%
Operating profit margin 6.93% 7.94% 7.44%
Profit ratio for the year 6.85% 4.68% 5.51%
TOP